Breaking News Instant updates and real-time market news.

ACER

Acer Therapeutics

$3.72

-0.04 (-1.06%)

08:33
07/05/19
07/05
08:33
07/05/19
08:33

Acer Therapeutics reduces headcount to 19 from 48 employees

ACER Acer Therapeutics
$3.72

-0.04 (-1.06%)

06/25/19
RAJA
06/25/19
DOWNGRADE
RAJA
Market Perform
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James
06/25/19
RAJA
06/25/19
DOWNGRADE
RAJA
Market Perform
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
As previously reported, Raymond James analyst Steven Seedhouse downgraded Acer Therapeutics to Market Perform from Outperform following the company's announcement this morning of the receipt of a complete response letter from the FDA for Edsivo. The analyst, who said he doesn't see a path forward for the drug in vascular Ehlers-Danlos Syndrome as he does not think conducting the required study is a viable option, removed Edsivo from his estimates and reduced his view of the probability of success for Acer's other programs.
06/25/19
ROTH
06/25/19
NO CHANGE
Target $9
ROTH
Buy
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
Roth Capital analyst Yasmeen Rahimi lowered her price target for Acer Therapeutics to $9 from $66 following the company's CRL letter from the FDA requesting a well-controlled trial, which stems from FDA's issue with the way BBEST was stopped early, despite lengthy discussions with regulators about this dating back to EDSIVO IND filing and agreement on how to treat stats from ultra-orphan data. With minimal clarity as to the future of EDSIVO, the analyst is removing EDSIVO from her valuation to focus on ACER-001. Rahimi reiterates a Buy rating on the shares.
06/26/19
HCWC
06/26/19
NO CHANGE
Target $10
HCWC
Buy
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
After Acer announced that lead product candidate Edsivo received a Complete Response Letter from the FDA, H.C. Wainwright analyst Raghuram Selvaraju called the action "surprising," noting that vascular Ehlers-Danlos Syndrome is an ultra-rare disease without any approved treatment and "it was agency reviewers who encouraged Acer to submit the drug for approval in the first place." The FDA trial request may take several years to fulfill and may not be practical to achieve given the rarity of the condition, said Selvaraju, who removed Edsivo from his projection and cut his price target on the stock to $10 from $55. He keeps a Buy rating on Acer shares, noting that its cash runway "remains relatively lengthy" and he expects Acer to now pivot to clinical development of ACER-001, a taste-masked, immediate-release formulation of sodium phenylbutyrate for treatment of urea cycle disorders and maple syrup urine disease.

TODAY'S FREE FLY STORIES

CMA

Comerica

$69.23

-2.52 (-3.51%)

05:26
07/18/19
07/18
05:26
07/18/19
05:26
Downgrade
Comerica rating change  »

Comerica downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

EBAY

eBay

$39.03

-0.87 (-2.18%)

05:26
07/18/19
07/18
05:26
07/18/19
05:26
Recommendations
eBay analyst commentary  »

eBay price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$362.50

-3.22 (-0.88%)

05:23
07/18/19
07/18
05:23
07/18/19
05:23
Recommendations
Netflix analyst commentary  »

Netflix content lineup…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$217.73

12.67 (6.18%)

05:20
07/18/19
07/18
05:20
07/18/19
05:20
Downgrade
ASML rating change  »

ASML downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$90.11

0.99 (1.11%)

05:20
07/18/19
07/18
05:20
07/18/19
05:20
Earnings
Novartis raises FY19 revenue view to up mid to high-single digit »

Novartis provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 25

    Sep

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

05:18
07/18/19
07/18
05:18
07/18/19
05:18
Upgrade
Skyworks rating change  »

Skyworks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$203.32

-1.08 (-0.53%)

05:18
07/18/19
07/18
05:18
07/18/19
05:18
Upgrade
Apple rating change  »

Apple upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

05:16
07/18/19
07/18
05:16
07/18/19
05:16
Downgrade
Skyworks rating change  »

Skyworks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$75.75

0.09 (0.12%)

05:15
07/18/19
07/18
05:15
07/18/19
05:15
Downgrade
Qualcomm rating change  »

Qualcomm downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

VET

Vermilion Energy

$21.12

-0.44 (-2.04%)

05:14
07/18/19
07/18
05:14
07/18/19
05:14
Downgrade
Vermilion Energy rating change  »

Vermilion Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

XOM

Exxon Mobil

$75.49

-0.44 (-0.58%)

05:13
07/18/19
07/18
05:13
07/18/19
05:13
Downgrade
Exxon Mobil rating change  »

Exxon Mobil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TTD

Trade Desk

$244.23

0.72 (0.30%)

05:12
07/18/19
07/18
05:12
07/18/19
05:12
Downgrade
Trade Desk rating change  »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$90.11

0.99 (1.11%)

05:11
07/18/19
07/18
05:11
07/18/19
05:11
Earnings
Novartis reports Q2 core EPS $1.34, consensus $1.22 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 25

    Sep

IHG

InterContinental

$69.80

-0.16 (-0.23%)

05:11
07/18/19
07/18
05:11
07/18/19
05:11
Downgrade
InterContinental rating change  »

InterContinental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WTBDY

Whitbread

$0.00

(0.00%)

05:10
07/18/19
07/18
05:10
07/18/19
05:10
Downgrade
Whitbread rating change  »

Whitbread downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$28.85

-0.555 (-1.89%)

05:08
07/18/19
07/18
05:08
07/18/19
05:08
Downgrade
MGM Resorts rating change  »

MGM Resorts downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

EXP

Eagle Materials

$86.46

-0.245 (-0.28%)

05:06
07/18/19
07/18
05:06
07/18/19
05:06
Downgrade
Eagle Materials rating change  »

Eagle Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

  • 21

    Aug

  • 04

    Sep

  • 13

    Nov

ATI

Allegheny Technologies

$24.47

-0.415 (-1.67%)

05:05
07/18/19
07/18
05:05
07/18/19
05:05
Downgrade
Allegheny Technologies rating change  »

Allegheny Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

ARNC

Arconic

$25.29

-0.49 (-1.90%)

05:05
07/18/19
07/18
05:05
07/18/19
05:05
Downgrade
Arconic rating change  »

Arconic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USCR

U.S. Concrete

$50.87

-0.96 (-1.85%)

05:04
07/18/19
07/18
05:04
07/18/19
05:04
Downgrade
U.S. Concrete rating change  »

U.S. Concrete downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 13

    Nov

AMD

AMD

$33.59

-0.23 (-0.68%)

, INTC

Intel

$49.39

0.22 (0.45%)

04:59
07/18/19
07/18
04:59
07/18/19
04:59
Downgrade
AMD downgraded to Neutral from Buy at Mizuho »

Mizuho analyst Vijay…

AMD

AMD

$33.59

-0.23 (-0.68%)

INTC

Intel

$49.39

0.22 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

04:55
07/18/19
07/18
04:55
07/18/19
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 7/13 Jobless…

04:55
07/18/19
07/18
04:55
07/18/19
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

GMRE

Global Medical REIT

$10.51

-0.15 (-1.41%)

04:55
07/18/19
07/18
04:55
07/18/19
04:55
Conference/Events
Global Medical REIT management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

TORC

ResTORbio

$10.42

0.19 (1.86%)

04:55
07/18/19
07/18
04:55
07/18/19
04:55
Conference/Events
ResTORbio management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.